These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1638080)

  • 1. A probable mechanism for hyperpigmentation by fotemustine.
    Schallreuter KU; Ring J
    Dermatology; 1992; 185(1):76-7. PubMed ID: 1638080
    [No Abstract]   [Full Text] [Related]  

  • 2. Serpentine supravenous hyperpigmentation induced by the nitrosourea fotemustine.
    Claudy AL; Lévigne V; Boucheron S
    Dermatology; 1992; 184(1):70-2. PubMed ID: 1559000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fotemustine for the treatment of melanoma.
    Quéreux G; Dréno B
    Expert Opin Pharmacother; 2011 Dec; 12(18):2891-904. PubMed ID: 22077794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fotemustine-related leukoencephalopathy.
    Renard D; Stoebner P; Campello C; Meunier L
    Acta Neurol Belg; 2013 Sep; 113(3):365-6. PubMed ID: 23229621
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurological toxicity during metastatic melanoma treatment with fotemustine.
    Khalil Z; Pageot N; Carlander B; Guillot B
    Melanoma Res; 2005 Dec; 15(6):563-4. PubMed ID: 16314745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent thrombocytopenia during melanoma treatment with fotemustine.
    Turrisi G; Sozzi P; Marinozzi C; Clerico MA
    Melanoma Res; 2006 Dec; 16(6):543-4. PubMed ID: 17119456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fotemustine: muphoran].
    Avril MF
    Ann Dermatol Venereol; 2007 Dec; 134(12):997-1000. PubMed ID: 18166925
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
    Gill S; Shapiro J; Westerman D; Prince HM
    J Clin Oncol; 2007 Oct; 25(28):4493-4. PubMed ID: 17906211
    [No Abstract]   [Full Text] [Related]  

  • 9. [New toxicity of fotemustine: diffuse interstitial lung disease].
    Bertrand M; Wémeau-Stervinou L; Gauthier S; Auffret M; Mortier L
    Ann Dermatol Venereol; 2012 Apr; 139(4):277-81. PubMed ID: 22482481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
    Pathol Biol (Paris); 1990 Oct; 38(8):876-80. PubMed ID: 2274396
    [No Abstract]   [Full Text] [Related]  

  • 11. [Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
    Perrot JL; Lanthier K; Benoit F; Graille MC; Guy C; Bertheas MF; Cambazard F
    Ann Dermatol Venereol; 1995; 122(10):663-6. PubMed ID: 8687048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity and resistance in human metastatic melanoma to the new chloroethylnitrosourea anti-tumor drug Fotemustine.
    Schallreuter KU; Wood JM
    Biochim Biophys Acta; 1991 Jun; 1096(4):277-83. PubMed ID: 2065101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients.
    Dumontet C; Jaubert J; Sebban C; Bouafia F; Ardiet C; Tranchand B; Berger E; Lucas C; Guyotat D; Coiffier B
    Ann Oncol; 2003 Apr; 14(4):615-22. PubMed ID: 12649110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC.
    Addeo R; Zappavigna S; Luce A; Facchini S; Caraglia M
    Expert Opin Drug Saf; 2013 Sep; 12(5):729-40. PubMed ID: 23560594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of hepatotoxicity but loss of antimelanoma effect with combined fotemustine and anti-oxidant treatment.
    Webster GJ; Kurtovic J; Singh-Grewal I; Friedlander M; Riordan SM
    Intern Med J; 2004 May; 34(5):298-9. PubMed ID: 15151681
    [No Abstract]   [Full Text] [Related]  

  • 16. [Interspecies comparison of pharmacokinetic parameters of fotemustine (nitrosourea S 10036): mice, rats, monkeys, dogs and man].
    Lucas C; Ings B; Gray AJ; Deloffre P; Lokiec F; Campbell B; Beerblock K
    Bull Cancer; 1989; 76(8):863-5. PubMed ID: 2515897
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients.
    Mangiacavalli S; Pica G; Varettoni M; Lazzarino M; Corso A
    Eur J Haematol; 2009 Mar; 82(3):240-1. PubMed ID: 19018860
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatic intra-arterial infusion of fotemustine: pharmacokinetics.
    Fety R; Lucas C; Solere P; Cour V; Vignoud J
    Cancer Chemother Pharmacol; 1992; 31(2):118-22. PubMed ID: 1451232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of metastatic uveal melanoma with intravenous fotemustine.
    Spagnolo F; Grosso M; Picasso V; Tornari E; Pesce M; Queirolo P
    Melanoma Res; 2013 Jun; 23(3):196-8. PubMed ID: 23624366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
    J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.